Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Aug 28;14(1):112.
doi: 10.1186/s13048-021-00862-5.

Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis

Jue Zhu  1 , Lifeng Yan  1 , Qiming Wang  2
Affiliations
Meta-Analysis

Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis

Jue Zhu et al. J Ovarian Res. .

Abstract

Several studies have evaluated the efficacy of PD-1/PD-L1 inhibitors in ovarian cancer; however, the response rate varies. This study aims to explore the efficacy of anti-PD-1/PD-L1 therapy in ovarian cancer. A quantitative meta-analysis was performed through a systematic search in PubMed, Web of Science, and the Cochrane Library. The pooled ORR was calculated and compared. Fifteen trials were included in this meta-analysis. Our analyses showed that the pooled ORR of all included studies was 19% (95% CI: 13%, 27%). Single PD-1/PD-L1 inhibitors had the lowest ORR of 9% (95% CI: 7%, 12%), while the combination of PD-1/PD-L1 inhibitors and chemotherapy had the highest ORR of 36% (95% CI: 24%, 51%). This study showed that PD-1/PD-L1 inhibitors alone have limited efficacy for ovarian cancer. The combination of PD-1/PD-L1 inhibitors and chemotherapy could be chosen as the recommended modality for further study.

Keywords: Immunotherapy; Ovarian cancer; PD-1/PD-L1 inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors have stated that they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
The flow diagram of this meta-analysis
Fig. 2
Fig. 2
Summary overall response rate for all included studies
Fig. 3
Fig. 3
Summary overall response rate for different treatment combination. Summary overall response rate for single PD-1/PD-L1 inhibitors (A), PD-1/PD-L1 inhibitors combined with chemotherapy (B), PD-1/PD-L1 inhibitors combined with antiangiogenic therapy (C), and PD-1/PD-L1 inhibitors combined with PARP inhibitors (D)
Fig. 4
Fig. 4
Summary overall response rate for platinum-resistant and platinum-sensitive ovarian cancer
Fig. 5
Fig. 5
Summary overall response rate for platinum-resistant and platinum-sensitive ovarian cancer excluding treatment arms with a single PD-1/PD-L1 inhibitor
Fig. 6
Fig. 6
Begg’s funnel plot for overall response rate
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. - PubMed
    1. Jessmon P, Boulanger T, Zhou W, Patwardhan P. Epidemiology and treatment patterns of epithelial ovarian cancer. Expert Rev Anticancer Ther. 2017;17:427–437. doi: 10.1080/14737140.2017.1299575. - DOI - PubMed
    1. Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med Oncol. 2017;34:103. doi: 10.1007/s12032-017-0960-z. - DOI - PubMed
    1. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376–1388. doi: 10.1016/S0140-6736(13)62146-7. - DOI - PubMed
    1. Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30:1080–1087. doi: 10.1093/annonc/mdz135. - DOI - PubMed

Publication types

MeSH terms

Substances